Identification of dual ligands targeting angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ by core hopping of telmisartan

It has been reported previously that some angiotensin II receptor blockers not only antagonize angiotensin II type 1 receptor (AT1R), but also exert stimulation in peroxisome proliferator-activated receptor γ (PPARγ) partial activation, among which telmisartan displays the best. Telmisartan has been tested as a bifunctional ligand with antihypertensive and hypoglycemic activity. Aiming at more potent leads with selective AT1R antagonism and PPARγ partial agonism, the three parts of telmisartan including the distal benzimidazole ring, the biphenyl moiety, and the carboxylic acid group experienced modification by core hopping method in our study. The central benzimidazole ring, however, remained intact considering its great affinity toward AT1R and PPARγ. We utilized computational techniques for the sake of details on the binding interactions and conformational stability. Standard precision docking analysis and absorption, distribution, metabolism, excretion, and toxicity prediction received 10 molecules with higher Glide scores, similar interactions, and improved pharmacokinetic profiles compared to telmisartan. Comp#91 with highest scores for AT1R (−11.92 kcal/mol) and PPARγ (−13.88 kcal/mol) exhibited excellent binding modes and pharmacokinetic parameters. Molecular dynamics trajectories on best docking pose of comp#91 confirmed the docking results and verified the conformational stability with both receptors throughout the course of 20-ns simulations. Thus, comp#91 could be identified as a promising lead in the development of dual AT1R antagonist and PPARγ partial agonist against hypertension and type 2 diabetes.

[1]  Hui-Ding Xie,et al.  An Investigation of Molecular Docking and Molecular Dynamic Simulation on Imidazopyridines as B-Raf Kinase Inhibitors , 2015, International journal of molecular sciences.

[2]  Brin Freund,et al.  A Novel Role for Calpain in the Endothelial Dysfunction Induced by Activation of Angiotensin II Type 1 Receptor Signaling , 2011, Circulation research.

[3]  Dibyabhaba Pradhan,et al.  Para-(benzoyl)-phenylalanine as a potential inhibitor against LpxC of Leptospira spp.: homology modeling, docking, and molecular dynamics study , 2014, Journal of biomolecular structure & dynamics.

[4]  Dibyabhaba Pradhan,et al.  Genome-based approaches to develop epitope-driven subunit vaccines against pathogens of infective endocarditis , 2014, Journal of biomolecular structure & dynamics.

[5]  D. Grillot,et al.  Discovery of novel indazole derivatives as dual angiotensin II antagonists and partial PPARγ agonists. , 2014, Bioorganic & medicinal chemistry letters.

[6]  Federico D. Sacerdoti,et al.  Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters , 2006, ACM/IEEE SC 2006 Conference (SC'06).

[7]  M. Murugan,et al.  Molecular screening of insecticides with sigma glutathione S-transferases (GST) in cotton aphid Aphis gossypii using docking , 2014, Bioinformation.

[8]  L. Steinaa,et al.  Activation of peroxisome proliferator–activated receptor gamma induces anti-inflammatory properties in the chicken free avian respiratory macrophages , 2015, Journal of animal science and technology.

[9]  Sébastien Boutet,et al.  Structure of the Angiotensin Receptor Revealed by Serial Femtosecond Crystallography , 2015, Cell.

[10]  J. Violin,et al.  TRV120027, a Novel &bgr;-Arrestin Biased Ligand at the Angiotensin II Type I Receptor, Unloads the Heart and Maintains Renal Function When Added to Furosemide in Experimental Heart Failure , 2012, Circulation. Heart failure.

[11]  R. Larson,et al.  Molecular dynamics simulations of model trans-membrane peptides in lipid bilayers: a systematic investigation of hydrophobic mismatch. , 2006, Biophysical journal.

[12]  A. D'Angelo,et al.  Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone , 2007, Journal of clinical pharmacy and therapeutics.

[13]  Julio Caballero,et al.  Study of the Differential Activity of Thrombin Inhibitors Using Docking, QSAR, Molecular Dynamics, and MM-GBSA , 2015, PloS one.

[14]  Mohammed I Alhazmi.  Molecular docking of selected phytocompounds with H1N1 Proteins , 2015, Bioinformation.

[15]  J Polanski,et al.  Pharmacophore-based database mining for probing fragmental drug-likeness of diketo acid analogues , 2012, SAR and QSAR in environmental research.

[16]  R. Leduc,et al.  Identification of Distinct Conformations of the Angiotensin-II Type 1 Receptor Associated with the Gq/11 Protein Pathway and the β-Arrestin Pathway Using Molecular Dynamics Simulations* , 2015, Journal of Biological Chemistry.

[17]  Umesh Yadava,et al.  Stabilization of Microtubules by Taxane Diterpenoids: Insight from Docking and MD simulations , 2015, Journal of biological physics.

[18]  J. Sangshetti,et al.  Synthesis, docking and ADMET prediction of novel 5-((5-substituted-1-H-1,2,4-triazol-3-yl) methyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine as antifungal agents , 2014 .

[19]  Ryan T. Strachan,et al.  Allosteric Modulation of β-Arrestin-biased Angiotensin II Type 1 Receptor Signaling by Membrane Stretch* , 2014, The Journal of Biological Chemistry.

[20]  Devesh Kumar,et al.  Pyrazolo[3,4-d]pyrimidines as novel inhibitors of O-acetyl-l-serine sulfhydrylase of Entamoeba histolytica: an in silico study , 2015, Journal of Molecular Modeling.

[21]  J. Violin,et al.  Cardiorenal Actions of TRV 120027 , a Novel ß-Arrestin – Biased Ligand at the Angiotensin II Type I Receptor , in Healthy and Heart Failure Canines A Novel Therapeutic Strategy for Acute Heart Failure , 2011 .

[22]  M. Bagiński,et al.  Structural and dynamic changes adopted by EmrE, multidrug transporter protein--Studies by molecular dynamics simulation. , 2015, Biochimica et biophysica acta.

[23]  Selvaraman Nagamani,et al.  In silico studies on marine actinomycetes as potential inhibitors for Glioblastoma multiforme , 2011, Bioinformation.

[24]  P. Groundwater,et al.  Identification of dual PPARα/γ agonists and their effects on lipid metabolism. , 2015, Bioorganic & medicinal chemistry.

[25]  E. Benfenati,et al.  Comparison of in silico models for prediction of Daphnia magna acute toxicity , 2014, SAR and QSAR in environmental research.

[26]  W. Sippl,et al.  Homology modeling of parasite histone deacetylases to guide the structure-based design of selective inhibitors. , 2015, Journal of molecular graphics & modelling.

[27]  D. Sharmila,et al.  Molecular simulation of N-acetylneuraminic acid analogs and molecular dynamics studies of cholera toxin-Neu5Gc complex , 2015, Journal of biomolecular structure & dynamics.

[28]  Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses , 2015, Drug design, development and therapy.

[29]  K. Node,et al.  Structure-Function Basis of Attenuated Inverse Agonism of Angiotensin II Type 1 Receptor Blockers for Active-State Angiotensin II Type 1 Receptor , 2015, Molecular Pharmacology.

[30]  J. Violin,et al.  Cardiorenal Actions of TRV120027, a Novel ß-Arrestin–Biased Ligand at the Angiotensin II Type I Receptor, in Healthy and Heart Failure Canines: A Novel Therapeutic Strategy for Acute Heart Failure , 2011, Circulation. Heart failure.

[31]  Shu-Qing Wang,et al.  Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors , 2012, PloS one.

[32]  M. Chatzopoulou,et al.  1-Hydroxypyrazole as a bioisostere of the acetic acid moiety in a series of aldose reductase inhibitors. , 2013, Bioorganic & medicinal chemistry.

[33]  K. Pegklidou,et al.  Design and synthesis of novel series of pyrrole based chemotypes and their evaluation as selective aldose reductase inhibitors. A case of bioisosterism between a carboxylic acid moiety and that of a tetrazole. , 2010, Bioorganic & medicinal chemistry.

[34]  P. Markt,et al.  Characterization of new PPARgamma agonists: benzimidazole derivatives-importance of positions 5 and 6, and computational studies on the binding mode. , 2010, Bioorganic & medicinal chemistry.

[35]  Antti Poso,et al.  Comparative molecular field analysis and molecular dynamics studies of α/β hydrolase domain containing 6 (ABHD6) inhibitors , 2015, Journal of Molecular Modeling.

[36]  A. Tiwari,et al.  In silico docking of methyl isocyanate (MIC) and its hydrolytic product (1, 3-dimethylurea) shows significant interaction with DNA Methyltransferase 1 suggests cancer risk in Bhopal-Gas- Tragedy survivors. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[37]  Stefan Senger,et al.  Using Tversky Similarity Searches for Core Hopping: Finding the Needles in the Haystack , 2009, J. Chem. Inf. Model..

[38]  Ying Sun,et al.  New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy , 2014, PPAR research.

[39]  O. Yasuda,et al.  Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity. , 2011, Biochemical and biophysical research communications.

[40]  J. Chen,et al.  Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ. , 2013, Bioorganic & medicinal chemistry letters.

[41]  U. Yadava,et al.  Molecular dynamics simulation of hydrated d(CGGGTACCCG)4 as a four-way DNA Holliday junction and comparison with the crystallographic structure , 2016 .

[42]  M. Coumar,et al.  Synthesis, pharmacological assessment, molecular modeling and in silico studies of fused tricyclic coumarin derivatives as a new family of multifunctional anti-Alzheimer agents. , 2016, European journal of medicinal chemistry.

[43]  Scott A. Busby,et al.  Anti-Diabetic Actions of a Non-Agonist PPARγ Ligand Blocking Cdk5-Mediated Phosphorylation , 2011, Nature.

[44]  John J Irwin,et al.  Using ZINC to Acquire a Virtual Screening Library , 2008, Current protocols in bioinformatics.

[45]  A. D'Angelo,et al.  Telmisartan and Irbesartan Therapy in Type 2 Diabetic Patients Treated with Rosiglitazone: Effects on Insulin-Resistance, Leptin and Tumor Necrosis Factor-α , 2006, Hypertension Research.

[46]  M. Mallavarapu,et al.  In Silico Approach to Support that p-Nitrophenol Monooxygenase from Arthrobacter sp. Strain JS443 Catalyzes the Initial Two Sequential Monooxygenations , 2015, Interdisciplinary Sciences: Computational Life Sciences.

[47]  H. Yoshimatsu,et al.  Telmisartan effectively improves insulin sensitivity in hypertensive patients with insulin resistance. , 2011, Obesity research & clinical practice.

[48]  R. Negro,et al.  The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients , 2006, Journal of endocrinological investigation.

[49]  Woody Sherman,et al.  Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.

[50]  Jan Jakubík,et al.  Towards predictive docking at aminergic G-protein coupled receptors , 2015, Journal of Molecular Modeling.

[51]  Xinping Luo,et al.  Docking-based virtual screening of potential human P2Y12 receptor antagonists. , 2011, Acta biochimica et biophysica Sinica.

[52]  K. Muthusamy,et al.  Molecular modeling, quantum polarized ligand docking and structure-based 3D-QSAR analysis of the imidazole series as dual AT1 and ETA receptor antagonists , 2013, Acta Pharmacologica Sinica.

[53]  E. Oetjen.  Antidiabetic actions of a non–agonist PPARγ ligand blocking Cdk5–mediated phosphorylation , 2012 .

[54]  J. Encinar,et al.  In silico approach for the discovery of new PPARγ modulators among plant-derived polyphenols , 2015, Drug design, development and therapy.

[55]  K. Ohno,et al.  Structural basis for telmisartan-mediated partial activation of PPAR gamma , 2012, Hypertension Research.

[56]  Raymond C. Stevens,et al.  Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor*♦ , 2015, The Journal of Biological Chemistry.

[57]  N. Gresh,et al.  Design of Group IIA Secreted/Synovial Phospholipase A2 Inhibitors: An Oxadiazolone Derivative Suppresses Chondrocyte Prostaglandin E2 Secretion , 2010, PloS one.

[58]  S. Jana,et al.  Recognition properties of carboxylic acid bioisosteres: anion binding by tetrazoles, aryl sulfonamides, and acyl sulfonamides on a calix[4]arene scaffold. , 2011, The Journal of organic chemistry.

[59]  Hyeon Joo,et al.  OPM database and PPM web server: resources for positioning of proteins in membranes , 2011, Nucleic Acids Res..

[60]  Mitchell A. Avery,et al.  Identification of Telmisartan as a Unique Angiotensin II: Receptor Antagonist With Selective PPARγ–Modulating Activity , 2004, Hypertension.

[61]  L. Saleena,et al.  Combined structure- and ligand-based pharmacophore modeling and molecular dynamics simulation studies to identify selective inhibitors of MMP-8 , 2014, Journal of Molecular Modeling.

[62]  N. Tajima,et al.  Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. , 2007, American journal of hypertension.

[63]  B. Staels,et al.  Thiazolidinediones and PPARγ agonists: time for a reassessment , 2012, Trends in Endocrinology & Metabolism.

[64]  G. Jagadeesh,et al.  Structural determinants for binding, activation, and functional selectivity of the angiotensin AT1 receptor. , 2014, Journal of molecular endocrinology.

[65]  Xiaolei Zhu,et al.  Characterization of the binding of angiotensin II receptor blockers to human serum albumin using docking and molecular dynamics simulation , 2010, Journal of molecular modeling.

[66]  P. Svensson,et al.  Synthesis and functionalization of cyclic sulfonimidamides: a novel chiral heterocyclic carboxylic Acid bioisostere. , 2012, ACS medicinal chemistry letters.

[67]  Constantinos Potamitis,et al.  Insights into AT1 Receptor Activation through AngII Binding Studies , 2013, J. Chem. Inf. Model..

[68]  Shanthi Nagarajan,et al.  Homology modeling, molecular dynamics, e-pharmacophore mapping and docking study of Chikungunya virus nsP2 protease , 2011, Journal of Molecular Modeling.

[69]  Georgios Archontis,et al.  Kinetics, in silico docking, molecular dynamics, and MM‐GBSA binding studies on prototype indirubins, KT5720, and staurosporine as phosphorylase kinase ATP‐binding site inhibitors: The role of water molecules examined , 2011, Proteins.

[70]  Xiaobo Li,et al.  SAHA-based novel HDAC inhibitor design by core hopping method. , 2014, Journal of molecular graphics & modelling.